- 专利标题: Bromodomain inhibitor
-
申请号: US15788741申请日: 2017-10-19
-
公开(公告)号: US10702517B2公开(公告)日: 2020-07-07
- 发明人: Juan Manuel Betancort , Jeffrey Alan Stafford , Ryan Stansfield , James Marvin Veal
- 申请人: Celgene Quanticel Research, Inc.
- 申请人地址: US CA San Diego
- 专利权人: CELGENE QUANTICEL RESEARCH, INC.
- 当前专利权人: CELGENE QUANTICEL RESEARCH, INC.
- 当前专利权人地址: US CA San Diego
- 代理机构: Foley & Lardner LLP
- 主分类号: A61K31/472
- IPC分类号: A61K31/472 ; A61K47/32 ; A61K47/38 ; A61K9/10 ; A61K9/16 ; A61K9/20 ; C07D217/12 ; C07D217/24
摘要:
Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.
公开/授权文献
- US20180042914A1 BROMODOMAIN INHIBITOR 公开/授权日:2018-02-15